UAE, Aug. 12 -- Dubai, United Arab Emirates:Colon cancer is the third most common cancer in the world. While screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer - and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) - was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.